Skip to main content
Erschienen in: Journal of Cancer Education 1/2015

01.03.2015 | Reflection

Five Principles for Effective Cancer Clinical Trial Education Within the Community Setting

verfasst von: Margo Michaels, Natasha Blakeney, Aisha T. Langford, Marvella E. Ford

Erschienen in: Journal of Cancer Education | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Abstract

Participation in cancer clinical trials (CCTs) is a key measure for delivery of quality cancer care. Yet, adult cancer patient participation in CCTs remains at about 3 %, and participation rates are even lower among ethnic and racial minorities and the medically underserved. Social justice demands better representation of all populations in CCTs to ensure equal access to clinical trials and to ensure greater generalizability of trial results. Using a conceptual framework, this paper outlines a set of guiding principles deemed essential for effective and ethical implementation of community-based education in CCTs. Also described are examples of interventions related to this framework that have been used to overcome key barriers to trial enrollment among underserved populations. Application of the key principles, combined with ongoing engagement of cancer care institutions, suggests promise in enhancing trial participation.
Fußnoten
1
As described in the Belmont Report,: justice “means the sense of ‘fairness in distribution’ or ‘what is deserved.’” An injustice occurs when some benefit to which a person is entitled is denied without good reason or when some burden is imposed unduly. “Questions of justice have long been associated with social practices such as punishment, taxation and political representation…and have not generally been associated with scientific research. However, conceptions of justice are relevant to research involving human subjects” (http://​www.​hhs.​gov/​ohrp/​humansubjects/​guidance/​belmont.​htm).
 
Literatur
2.
Zurück zum Zitat Nass SJ, Moses HL, Mendelsohn J (eds) (2010) National Cancer Clinical Trials System for the 21st Century: reinvigorating the NCI Cooperative Group Program. Committee on Cancer Clinical Trials and the NCI Cooperative Group Program. Institute of Medicine of the National Academies. Nass SJ, Moses HL, Mendelsohn J (eds) (2010) National Cancer Clinical Trials System for the 21st Century: reinvigorating the NCI Cooperative Group Program. Committee on Cancer Clinical Trials and the NCI Cooperative Group Program. Institute of Medicine of the National Academies.
3.
Zurück zum Zitat Brawley OW (2004) The study of accrual to clinical trials: can we learn from studying who enters our studies? J Clin Oncol 22:2039–2040CrossRefPubMed Brawley OW (2004) The study of accrual to clinical trials: can we learn from studying who enters our studies? J Clin Oncol 22:2039–2040CrossRefPubMed
4.
Zurück zum Zitat Murthy VH, Krumholz HM, Gross CP (2004) Participation in cancer clinical trials: race-, sex-, and age-based disparities. J Am Med Assoc 291:2720–2726CrossRef Murthy VH, Krumholz HM, Gross CP (2004) Participation in cancer clinical trials: race-, sex-, and age-based disparities. J Am Med Assoc 291:2720–2726CrossRef
5.
Zurück zum Zitat Stewart JH, Bertoni AG, Staten JL et al (2007) Participation in surgical oncology clinical trials: gender-, race/ethnicity-, and age-based disparities. Ann Surg Oncol 14(12):3328–3334CrossRefPubMed Stewart JH, Bertoni AG, Staten JL et al (2007) Participation in surgical oncology clinical trials: gender-, race/ethnicity-, and age-based disparities. Ann Surg Oncol 14(12):3328–3334CrossRefPubMed
6.
Zurück zum Zitat Simon MS, Du W (2004) Factors associated with breast cancer clinical trials participation and enrollment at a large academic medical center. J Clin Oncol 22:2046–2052CrossRefPubMed Simon MS, Du W (2004) Factors associated with breast cancer clinical trials participation and enrollment at a large academic medical center. J Clin Oncol 22:2046–2052CrossRefPubMed
7.
Zurück zum Zitat Galen J, Dohan D (2009) Diversity of participants in clinical trials in an academic medical center: the role of the ‘good study patient? Cancer 115:608–615CrossRef Galen J, Dohan D (2009) Diversity of participants in clinical trials in an academic medical center: the role of the ‘good study patient? Cancer 115:608–615CrossRef
8.
Zurück zum Zitat Ford JG, Howerton MW, Lai GY et al (2008) Barriers to recruiting underrepresented population to cancer clinical trials: a systematic review. Cancer 112(2):228–242CrossRefPubMed Ford JG, Howerton MW, Lai GY et al (2008) Barriers to recruiting underrepresented population to cancer clinical trials: a systematic review. Cancer 112(2):228–242CrossRefPubMed
9.
Zurück zum Zitat Wendler D, Kington R, Madans J et al (2006) Are racial and ethnic minorities less willing to participate in health research? PLoS Med 3(2):e19, Epub 2005CrossRefPubMedCentralPubMed Wendler D, Kington R, Madans J et al (2006) Are racial and ethnic minorities less willing to participate in health research? PLoS Med 3(2):e19, Epub 2005CrossRefPubMedCentralPubMed
10.
Zurück zum Zitat Ford JG, Howerton MW, Bolen S et al (2005) Knowledge and access to information on recruitment of underrepresented populations to cancer clinical trials. Summary Evidence Report/Technology Assessment. No. 122. AHRQ Publication No. 05-E019-1. Agency for Healthcare Research and Quality, Rockville Ford JG, Howerton MW, Bolen S et al (2005) Knowledge and access to information on recruitment of underrepresented populations to cancer clinical trials. Summary Evidence Report/Technology Assessment. No. 122. AHRQ Publication No. 05-E019-1. Agency for Healthcare Research and Quality, Rockville
11.
Zurück zum Zitat Ford ME, Siminoff LA, Pickelsimer E et al (2013) Unequal burden of disease, unequal participation in clinical trials: solutions from African American and Latino community members. Health Soc Work 38:29–38CrossRefPubMedCentralPubMed Ford ME, Siminoff LA, Pickelsimer E et al (2013) Unequal burden of disease, unequal participation in clinical trials: solutions from African American and Latino community members. Health Soc Work 38:29–38CrossRefPubMedCentralPubMed
12.
Zurück zum Zitat Ford ME, Wahlquist AE, Ridgeway C et al (2011) Evaluating an intervention to increase cancer knowledge in racially diverse communities in South Carolina. Patient Educ Couns 83:256–260CrossRefPubMedCentralPubMed Ford ME, Wahlquist AE, Ridgeway C et al (2011) Evaluating an intervention to increase cancer knowledge in racially diverse communities in South Carolina. Patient Educ Couns 83:256–260CrossRefPubMedCentralPubMed
13.
Zurück zum Zitat Ford ME, Havstad SL, Fields ME et al (2008) Effects of baseline comorbidities on cancer screening trial adherence among older African American men. Canc Epidemiol Biomarkers Prev 17:1234–1239, Epub 2008 May 7CrossRef Ford ME, Havstad SL, Fields ME et al (2008) Effects of baseline comorbidities on cancer screening trial adherence among older African American men. Canc Epidemiol Biomarkers Prev 17:1234–1239, Epub 2008 May 7CrossRef
14.
Zurück zum Zitat Langford A, Resnicow K, An L (2010) Clinical trial awareness among racial/ethnic minorities in HINTS 2007: sociodemographic, attitudinal, and knowledge correlates. J Health Commun Int Perspect 15(Suppl 3):92–101CrossRef Langford A, Resnicow K, An L (2010) Clinical trial awareness among racial/ethnic minorities in HINTS 2007: sociodemographic, attitudinal, and knowledge correlates. J Health Commun Int Perspect 15(Suppl 3):92–101CrossRef
15.
Zurück zum Zitat Corbie-Smith G, Thomas SB, St George DMM (2002) Distrust, race, and research. Arch Intern Med 162:2458–2463 Corbie-Smith G, Thomas SB, St George DMM (2002) Distrust, race, and research. Arch Intern Med 162:2458–2463
16.
Zurück zum Zitat Brown M, Moyer A (2010) Predictors of awareness of clinical trials and feelings about the use of medical information for research in a nationally representative US sample. Ethn Health 15:223–236CrossRefPubMed Brown M, Moyer A (2010) Predictors of awareness of clinical trials and feelings about the use of medical information for research in a nationally representative US sample. Ethn Health 15:223–236CrossRefPubMed
18.
Zurück zum Zitat Lara PN Jr, Paterniti DA, Chiechi C et al (2005) Evaluation of factors affecting awareness of and willingness to participate in cancer clinical trials. J Clin Oncol 23:9282–9289CrossRefPubMed Lara PN Jr, Paterniti DA, Chiechi C et al (2005) Evaluation of factors affecting awareness of and willingness to participate in cancer clinical trials. J Clin Oncol 23:9282–9289CrossRefPubMed
19.
Zurück zum Zitat UyBico SJ, Pavel S, Gross CP (2007) Recruiting vulnerable populations into research: a systematic review of recruitment interventions. J Gen Intern Med 22:852–863CrossRefPubMedCentralPubMed UyBico SJ, Pavel S, Gross CP (2007) Recruiting vulnerable populations into research: a systematic review of recruitment interventions. J Gen Intern Med 22:852–863CrossRefPubMedCentralPubMed
20.
Zurück zum Zitat Ellis PM, Butow PN, Tattersall MHN et al (2001) Randomized clinical trials in oncology: understanding and attitudes predict willingness to participate. J Clin Oncol 19:3554–3561PubMed Ellis PM, Butow PN, Tattersall MHN et al (2001) Randomized clinical trials in oncology: understanding and attitudes predict willingness to participate. J Clin Oncol 19:3554–3561PubMed
21.
Zurück zum Zitat Baquet CR, Commiskey P, Mullins CD et al (2006) Recruitment and participation in clinical trials: socio-demographic, rural/urban, and health care access predictors. Cancer Detect Prev 30:24–33CrossRefPubMedCentralPubMed Baquet CR, Commiskey P, Mullins CD et al (2006) Recruitment and participation in clinical trials: socio-demographic, rural/urban, and health care access predictors. Cancer Detect Prev 30:24–33CrossRefPubMedCentralPubMed
22.
Zurück zum Zitat Michaels M, Weiss ES, Guidry JA et al (2012) The promise of community-based advocacy and education efforts for increasing cancer clinical trials accrual. J Cancer Educ 27:67–74CrossRefPubMed Michaels M, Weiss ES, Guidry JA et al (2012) The promise of community-based advocacy and education efforts for increasing cancer clinical trials accrual. J Cancer Educ 27:67–74CrossRefPubMed
23.
Zurück zum Zitat Ford M, Wahlquist A, Blake R et al (2012) Assessing an intervention to improve clinical trial perceptions among predominately African-American communities in South Carolina. Prog Community Health Partnerships Res Educ Action 6:249–263CrossRef Ford M, Wahlquist A, Blake R et al (2012) Assessing an intervention to improve clinical trial perceptions among predominately African-American communities in South Carolina. Prog Community Health Partnerships Res Educ Action 6:249–263CrossRef
24.
Zurück zum Zitat Ford ME, Havstad SL, Vernon SW et al (2006) Enhancing adherence among older African American men enrolled in a longitudinal cancer screening trial. The Gerontologist 46:545–550CrossRefPubMed Ford ME, Havstad SL, Vernon SW et al (2006) Enhancing adherence among older African American men enrolled in a longitudinal cancer screening trial. The Gerontologist 46:545–550CrossRefPubMed
25.
Zurück zum Zitat Ma GX, Tan Y, Blakeney NC, Seals BF, Ma XS, Zhai S, Liu A, Tai Y, Michaels M (2014) The impact of a community-based clinical trial educational intervention among underrepresented Chinese Americans. Cancer Epidemiol Biomarkers Prev 23(3):424–432, Oct 3 Epub 2013CrossRefPubMed Ma GX, Tan Y, Blakeney NC, Seals BF, Ma XS, Zhai S, Liu A, Tai Y, Michaels M (2014) The impact of a community-based clinical trial educational intervention among underrepresented Chinese Americans. Cancer Epidemiol Biomarkers Prev 23(3):424–432, Oct 3 Epub 2013CrossRefPubMed
26.
Zurück zum Zitat Blakeney N, Michaels M, Green M, Richmond A, Long D, Robinson WS, Spicer C, Elliott-Bynum S, Corbie-Smith G (in press) Collaborative development of clinical trials education programs for African-American community-based organizations. J Canc Educ Blakeney N, Michaels M, Green M, Richmond A, Long D, Robinson WS, Spicer C, Elliott-Bynum S, Corbie-Smith G (in press) Collaborative development of clinical trials education programs for African-American community-based organizations. J Canc Educ
Metadaten
Titel
Five Principles for Effective Cancer Clinical Trial Education Within the Community Setting
verfasst von
Margo Michaels
Natasha Blakeney
Aisha T. Langford
Marvella E. Ford
Publikationsdatum
01.03.2015
Verlag
Springer US
Erschienen in
Journal of Cancer Education / Ausgabe 1/2015
Print ISSN: 0885-8195
Elektronische ISSN: 1543-0154
DOI
https://doi.org/10.1007/s13187-014-0699-6

Weitere Artikel der Ausgabe 1/2015

Journal of Cancer Education 1/2015 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.